<DOC>
	<DOC>NCT01130025</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of Innohep® in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.</brief_summary>
	<brief_title>Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<criteria>Patients with a diagnosis of active cancer. Symptomatic and objectively confirmed VTE. ≥ 18 years of age or above the legal age of consent as per country specific regulations. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Signed informed consent. Life expectancy &lt; 6 months. Patients with basal cell carcinoma or nonmelanoma skin cancer. Creatinine clearance ≤ 20 ml/min. Contraindications to anticoagulation. Known hypersensitivity to the investigational product (Innohep®) or the reference product (warfarin). History of heparininduced thrombocytopenia (HIT). Prerandomisation therapeutic anticoagulant treatment for acute VTE administered for more than 72 hours prior to randomisation. Patients unlikely to comply with the protocol. Participation in another interventional study. Pregnant or breastfeeding women. Women of childbearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>